Rigel’s Fostamatinib and Kissei Pharmaceuticals progress with a Phase III trial of their medicine for Chronic Immune Thrombocytopenia patients

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that its collaboration partner, Kissei Pharmaceuticals Co., Ltd. (“Kissei”), has initiated a Phase 3 trial in Japan of fostamatinib disodium hexahydrate in adult patients with chronic immune thrombocytopenia (ITP). By comparing it with…

STORM therapeutics reveals advanced information showing in vivo efficiency and therapeutic evidence of idea for focusing on Ribonucleic Acid modifying enzymes.

The biotechnology organization, STORM Therapeutics concentrated on the exploration of tiny molecule therapies adjusting Ribonucleic Acid epigenetics declared today that Oliver Rausch, Chief Scientific Officer of STORM Therapeutics will for the 1st time disclose information on focusing Ribonucleic Acid modifying…